Valuation: VERE THER

Market Cap 994M 873M 820M 750M 1.4B 95.23B 1.41B 9.85B 3.82B 48.55B 3.73B 3.65B 157B P/E 2023
-4.47x
P/E 2024 -2.4x
Enterprise Value 540M 474M 445M 407M 761M 51.71B 767M 5.35B 2.07B 26.36B 2.03B 1.98B 85.48B EV / Sales 2023
46,430,598x
EV / Sales 2024 717,743x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
3 years 2.86
Extreme 2.8647
20.12
5 years 2.86
Extreme 2.8647
56.18
10 years 2.86
Extreme 2.8647
78
Manager TitleAgeSince
President - 2025-07-24
Date Insider Type Main position Quantity % Market Cap. Importance
7/25/25 Tender

Chief Technology Officer

538,331 0.6358%
7/25/25 Tender

Chief Administrative Officer

534,066 0.6308%
7/25/25 Tender

Founder

3,397,141 4.0125%

Financials

2023 2024
Net sales 11.76 10.32 9.7 8.87 16.57 1.13K 16.7 116.52 45.17 574.23 44.15 43.19 1.86K 32.33 28.38 26.68 24.39 45.57 3.1K 45.91 320.41 124.21 1.58K 121.42 118.76 5.12K
Net income -200M -176M -165M -151M -282M -19.16B -284M -1.98B -769M -9.77B -751M -735M -31.68B -199M -174M -164M -150M -280M -19.03B -282M -1.97B -763M -9.7B -746M -730M -31.46B
Net Debt -549M -482M -453M -414M -774M -52.59B -780M -5.44B -2.11B -26.81B -2.06B -2.02B -86.94B -454M -399M -375M -343M -640M -43.52B -645M -4.5B -1.75B -22.19B -1.71B -1.67B -71.94B
Logo VERE THER
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Employees
274
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. VERV Stock